Program
tambotatug pelitecan
Also written as “YL201”, “YL201 for Injection” and “Tambotatug pelitecan”.
Its studies are mostly in Small Cell Lung Carcinoma · Nasopharyngeal Carcinoma · Pancreatic Neoplasms · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediLink Therapeutics (Suzhou) | 1212 open or running | phase 3since Sep 23, 2024 | Jun 16, 2022 | Jan 2027phase 2 · NCT07208773 |
| Amgen | 11 open or running | phase 1since Mar 21, 2025 | Mar 21, 2025 | Jun 23, 2031phase 1 · NCT06898957 |
- Named in hoffmann la roche’s own pipeline as
RG6919 tambotatug pelitecan (MediLink)
, phase 1, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche, Fosun Pharma and Akesobio.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2022First study: phase 2 study in Advanced Solid TumorNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT05434234 · 312 planned · United States, Canada, China and more
- Sep 21, 2023Phase 2 study in Advanced Solid TumorMediLink Therapeutics (Suzhou) · NCT06057922 · 990 enrolled · China
- Jan 28, 2024Phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)MediLink Therapeutics (Suzhou) · NCT06241846 · 100 planned · China
- Apr 23, 2024Phase 1 study in Advanced Solid TumorsMediLink Therapeutics (Suzhou) · NCT06394414 · 187 enrolled · China
- Sep 23, 20242 phase 3 studiesMediLink Therapeutics (Suzhou) · NCT06612151, NCT06629597
- Mar 21, 2025Amgen’s first study: phase 1 study in Small Cell Lung CarcinomaNew to AmgenAmgen · NCT06898957 · 29 enrolled · United States, Canada, China and more
- Sep 28, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07208773 · 260 planned · China
- Nov 17, 2025Phase 2 study in RecurrenceMediLink Therapeutics (Suzhou) · NCT07258979 · 202 planned · China
- Feb 6, 2026Phase 2 study in Thoracic NeoplasmsMediLink Therapeutics (Suzhou) · NCT07407933 · 118 planned · United States, Belgium, France and more
- Mar 17, 2026Phase 3 study in Advanced Esophageal Squamous Cell CarcinomaMediLink Therapeutics (Suzhou) · NCT07487896 · 440 planned · China
- Jul 28, 2026Phase 3 study in SCLC, Extensive StageMediLink Therapeutics (Suzhou) · NCT07739758 · 442 planned · China
- Aug 31, 2026Phase 3 study in Pancreatic NeoplasmsMediLink Therapeutics (Suzhou) · NCT07803783 · 320 planned · China
Ahead
- Jan 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07208773
- Feb 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)MediLink Therapeutics (Suzhou) · NCT06241846
- Apr 6, 2027Primary completion: phase 2 study in Advanced Solid TumorMediLink Therapeutics (Suzhou) · NCT05434234
- Apr 29, 2027Primary completion: phase 1 study in Advanced Solid TumorsMediLink Therapeutics (Suzhou) · NCT06394414
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically conjugated to an as of yet undisclosed topoisomerase-1 inhibitor via a tumor protease-cleavable linker, with potential antineoplastic ac…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) site-specifically ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07803783Pancreatic Neoplasms · China | 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) | Jan 2029 | 320 |
| NCT07739758SCLC, Extensive Stage · China | 3 | Recruiting | MediLink Therapeutics (Suzhou) | Jun 2029 | 442 |
| NCT07487896Advanced Esophageal Squamous Cell Carcinoma · China | 3 | Recruiting | MediLink Therapeutics (Suzhou) | Apr 30, 2028 | 440 |
| NCT07407933Thoracic Neoplasms · United States, Belgium, France and more | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Nov 2028 | 118 |
| NCT07258979Recurrence · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Feb 2028 | 202 |
| NCT07208773Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Jan 2027 | 260 |
| NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more | 1 | Active, not recruiting | Amgen | Jun 23, 2031 | 29 |
| NCT06629597Nasopharyngeal Carcinoma · China | 3 | Active, not recruiting | MediLink Therapeutics (Suzhou) | Dec 1, 2027 | 400 |
| NCT06612151Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | MediLink Therapeutics (Suzhou) | Dec 1, 2027 | 438 |
| NCT06394414Advanced Solid Tumors · China | 1 | Active, not recruiting | MediLink Therapeutics (Suzhou) | Apr 29, 2027 | 187 |
| NCT06241846Metastatic Castration-resistant Prostate Cancer (mCRPC) · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Feb 2027 | 100 |
| NCT06057922Advanced Solid Tumor · China | 2 | Active, not recruiting | MediLink Therapeutics (Suzhou) | Oct 2026 | 990 |
| NCT05434234Advanced Solid Tumor · United States, Canada, China and more | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Apr 6, 2027 | 312 |
How it is read
Names in the registry
- “YL201”, 11 entries
- “YL201 for Injection”, 2 entries
- “Tambotatug pelitecan”, 1 entry
- “YL201 and atezolizumab”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 3 studies
- Nasopharyngeal Carcinoma, 2 studies
- Pancreatic Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.